Radiochemicals for research and clinical use

BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, Cyclotron VU produces GMP- compliant medical isotopes in state-of-the-art manufacturing facilities. These products are used daily by pharmaceutical and biotechnology companies, medical device manufacturers, hospitals, clinics, and research laboratories.

High level of agreement between 124I-PET and 131I-imaging found

12/9/2016: Research from the university of Duisburg shows high level of agreement between 124I-PET and 131I-imaging. arrow

Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using (18)F-fluorocholine PET-CT

23/12/2015: Whereas conventional imaging consisting of neck ultrasound and 99Tcm-sestamibi SPECT-CT could not localize the pathological gland, subsequent FCH PET-CT clearly identified an adenoma dorsally of the left thyroid lobe in one patient arrow

Florbetaben is able to detect a form of beta-amyloid plaque that develops early in a brain affected by Alzheimer's disease

6/7/2015: Significant Florbetaben uptake in the frontal and posterior cingulate cortices was found in new PET scans. The new technology might enable the detection of Alzheimer's disease in its early stages. arrow

Our GMP-certificate has been successfully renewed

29/6/2015: Our new GMP-certificate reflects the status of our manufacturing site. Our customers can continue to rely fully on our high-quality, clinical grade production of radiopharmaceuticals and radiochemicals for medical diagnostics and research. arrow

89Zr-immuno-PET for imaging of long circulating drugs and disease targets

21/4/2015: A useful overview of the reagents, labeling protocols, quality tests and critical steps necessary to obtain high-quality 89Zr-conjugates. arrow

We are hiring!

11/2/2015: We have currently two exciting new job offers: a cyclotron operator mechanic and a cyclotron operator electronic engineer. arrow

89Zr-bevacizumab PET scans successfully visualizes tumor lesions in 22 patients

17/12/2014: 89Zr-bevacizumab PET scans enabled the visualization of 125 evaluable tumor lesions. This shows that tumor uptake of 89Zr-bevacizumab is high in mRCC, with great inter- and intra-patient heterogeneity. arrow